DK0758383T3 - Oplöselige polypeptidfraktioner af LAG-3-proteinet; fremgangsmåde til fremstilling; terapeutisk sammensætning; antiidiotypisk antistof - Google Patents

Oplöselige polypeptidfraktioner af LAG-3-proteinet; fremgangsmåde til fremstilling; terapeutisk sammensætning; antiidiotypisk antistof

Info

Publication number
DK0758383T3
DK0758383T3 DK95920125T DK95920125T DK0758383T3 DK 0758383 T3 DK0758383 T3 DK 0758383T3 DK 95920125 T DK95920125 T DK 95920125T DK 95920125 T DK95920125 T DK 95920125T DK 0758383 T3 DK0758383 T3 DK 0758383T3
Authority
DK
Denmark
Prior art keywords
lag
protein
manufacture
soluble polypeptide
therapeutic composition
Prior art date
Application number
DK95920125T
Other languages
Danish (da)
English (en)
Inventor
Florence Faure
Thierry Hercend
Bertrand Huard
Frederic Triebel
Original Assignee
Roussy Inst Gustave
Inst Nat Sante Rech Med
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussy Inst Gustave, Inst Nat Sante Rech Med, Applied Research Systems filed Critical Roussy Inst Gustave
Application granted granted Critical
Publication of DK0758383T3 publication Critical patent/DK0758383T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK95920125T 1994-05-06 1995-05-05 Oplöselige polypeptidfraktioner af LAG-3-proteinet; fremgangsmåde til fremstilling; terapeutisk sammensætning; antiidiotypisk antistof DK0758383T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9405643 1994-05-06
PCT/FR1995/000593 WO1995030750A2 (fr) 1994-05-06 1995-05-05 Fractions polypeptidiques solubles de la proteine lag-3; procede de production; composition therapeutique; anticorps anti-idiotype

Publications (1)

Publication Number Publication Date
DK0758383T3 true DK0758383T3 (da) 2007-05-29

Family

ID=9463004

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95920125T DK0758383T3 (da) 1994-05-06 1995-05-05 Oplöselige polypeptidfraktioner af LAG-3-proteinet; fremgangsmåde til fremstilling; terapeutisk sammensætning; antiidiotypisk antistof

Country Status (18)

Country Link
US (3) USRE38313E1 (de)
EP (1) EP0758383B1 (de)
JP (1) JP3700859B2 (de)
KR (1) KR100257466B1 (de)
CN (1) CN1110557C (de)
AT (1) ATE352617T1 (de)
BR (1) BR9507618A (de)
CA (1) CA2189657C (de)
DE (1) DE69535375T2 (de)
DK (1) DK0758383T3 (de)
ES (1) ES2281899T3 (de)
IL (1) IL113617A (de)
MX (1) MX9605365A (de)
NO (1) NO325828B1 (de)
PT (1) PT758383E (de)
RU (1) RU2178306C2 (de)
WO (1) WO1995030750A2 (de)
ZA (1) ZA953629B (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU701375B2 (en) 1995-07-21 1999-01-28 Institut Gustave Roussy Methods for detecting, identifying, isolating, and selectively labelling and targeting Th1 lymphocytes by means of the LAG-3 protein
WO1998023741A1 (fr) * 1996-11-28 1998-06-04 Institut Gustave Roussy Mutants de la proteine lag-3, leur expression et utilisation
EA003772B1 (ru) * 1996-11-29 2003-08-28 Апплайд Резеч Системз Арс Холдинг Н.В. Средство для обеспечения защиты трансплантата от отторжения иммунной системой хозяина на основе штамма генетически сконструированных эукариотических клеток, содержащих днк, кодирующую трансмембранный белок lag-3
EP0900841A1 (de) * 1997-06-18 1999-03-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Spleissvarianten von LAG-3
EP0893507A1 (de) * 1997-07-25 1999-01-27 Institut Gustave Roussy Verwendung von MHC Klass II Liganden (CD4 und LAG-3) als Adjuvanz für Impfungen und von LAG-3 in der Behandlung von Krebs
US6660843B1 (en) † 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6434012B2 (en) * 2000-02-11 2002-08-13 Tyco Electronics Logistics Ag Circuit board interconnect
WO2001083525A2 (en) * 2000-05-03 2001-11-08 Amgen Inc. Modified peptides, comprising an fc domain, as therapeutic agents
WO2003072035A2 (en) * 2002-02-22 2003-09-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
SI1897548T1 (sl) 2003-02-28 2013-12-31 The Johns Hopkins University Regulacija celic T
FR2868781B1 (fr) * 2004-04-13 2008-02-22 Immutep Composition de vaccin comprenant un ligand cmh de classe ii couple a un antigene, procede de preparation et utilisations
EP2044949A1 (de) 2007-10-05 2009-04-08 Immutep Verwendung von rekombinantem LAG-3 oder Derivaten daraus zur Auslösung einer Monozyten-Immunreaktion
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
AR091649A1 (es) * 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
BR122023024195A2 (pt) 2013-09-20 2023-12-26 Bristol-Myers Squibb Company Usos de anticorpos anti-lag-3 e anticorpos anti-pd-1
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
US20150259420A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
PL3148579T3 (pl) 2014-05-28 2021-07-19 Agenus Inc. Przeciwciała anty-gitr i sposoby ich zastosowania
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
EP3744340A3 (de) 2015-07-16 2021-03-03 Biokine Therapeutics Ltd. Zusammensetzungen und verfahren zur behandlung von krebs
GEP20227419B (en) 2015-07-30 2022-10-10 Macrogenics Inc Pd-1-binding molecules and methods of use thereof
WO2017025871A1 (en) 2015-08-07 2017-02-16 Glaxosmithkline Intellectual Property Development Limited Combination therapy comprising anti ctla-4 antibodies
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
US10306874B2 (en) * 2015-11-20 2019-06-04 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized lymphocyte-activation gene 3
US11447557B2 (en) 2015-12-02 2022-09-20 Agenus Inc. Antibodies and methods of use thereof
BR112018011781A2 (pt) 2015-12-14 2018-12-04 Macrogenics Inc molécula biespecífica possuindo um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de pd-1 e um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de ctla-4, e composição farmacêutica
AU2016371639A1 (en) 2015-12-16 2018-06-28 Merck Sharp & Dohme Llc Anti-LAG3 antibodies and antigen-binding fragments
WO2017136734A1 (en) * 2016-02-04 2017-08-10 Trianni, Inc. Enhanced production of immunoglobulins
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
EP3476399B1 (de) 2016-06-23 2022-04-20 Jiangsu Hengrui Medicine Co. Ltd. Lag-3-antikörper, antigenbindendes fragment davon und medizinische anwendung davon
MX2019003683A (es) 2016-10-11 2019-08-22 Agenus Inc Anticuerpos anti gen 3 de activación linfocítica (lag 3 ) y métodos para usarlos.
SG10201912940WA (en) * 2016-10-13 2020-02-27 Symphogen As Anti-lag-3 antibodies and compositions
TW201829462A (zh) 2016-11-02 2018-08-16 英商葛蘭素史克智慧財產（第二）有限公司 結合蛋白
KR20240058959A (ko) 2017-02-10 2024-05-07 리제너론 파마슈티칼스 인코포레이티드 면역-pet 이미지화를 위한 방사선 라벨링된 항-lag3 항체
MA49042A (fr) 2017-04-05 2020-02-12 Symphogen As Polythérapies ciblant pd-1, tim-3 et lag-3
US11339218B2 (en) * 2017-05-10 2022-05-24 Zhejiang Shimai Pharmaceutical Co., Ltd. Human monoclonal antibodies against LAG3 and uses thereof
CA3065304A1 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
HUE065242T2 (hu) 2017-05-30 2024-05-28 Bristol Myers Squibb Co LAG-3-pozitív tumorok kezelése
KR20200042937A (ko) 2017-08-30 2020-04-24 페인스 테라퓨틱스 인코포레이티드 항-lag-3 항체 및 이의 용도
CN111356476B (zh) 2017-12-22 2023-03-10 江苏恒瑞医药股份有限公司 Lag-3抗体药物组合物及其用途
CN113825527A (zh) 2019-05-13 2021-12-21 瑞泽恩制药公司 用于在治疗癌症中增强效力的pd-1抑制剂和lag-3抑制剂的组合
CN112010972B (zh) * 2019-05-31 2023-01-10 瑞阳(苏州)生物科技有限公司 与人lag-3蛋白结合的抗体及其编码基因和应用
CN110950966B (zh) * 2019-12-13 2020-12-11 启辰生生物科技(珠海)有限公司 融合蛋白、编码核酸和细胞及用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1762623A1 (de) 1988-01-22 2007-03-14 ZymoGenetics, Inc. Verfahren zur Produktion von biologisch aktiven Peptiddimeren
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5976877A (en) 1990-01-08 1999-11-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses
FR2656800B1 (fr) 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
EP0537293A4 (en) * 1990-07-02 1993-09-08 Bristol-Myers Company Ligand for cd28 receptor on b cells and methods

Also Published As

Publication number Publication date
BR9507618A (pt) 1997-08-19
CN1110557C (zh) 2003-06-04
US6143273A (en) 2000-11-07
PT758383E (pt) 2007-05-31
USRE38313E1 (en) 2003-11-11
AU2570195A (en) 1995-11-29
MX9605365A (es) 1997-12-31
IL113617A (en) 2007-09-20
WO1995030750A2 (fr) 1995-11-16
NO964650D0 (no) 1996-11-04
JPH09508023A (ja) 1997-08-19
JP3700859B2 (ja) 2005-09-28
CA2189657A1 (fr) 1995-11-16
WO1995030750A3 (fr) 1995-12-21
US5955300A (en) 1999-09-21
ATE352617T1 (de) 2007-02-15
CA2189657C (fr) 2002-03-12
NO964650L (no) 1997-01-06
IL113617A0 (en) 1995-08-31
EP0758383A1 (de) 1997-02-19
ZA953629B (en) 1996-11-05
KR970702917A (ko) 1997-06-10
KR100257466B1 (ko) 2000-07-01
RU2178306C2 (ru) 2002-01-20
WO1995030750A8 (fr) 1999-07-29
DE69535375D1 (de) 2007-03-15
EP0758383B1 (de) 2007-01-24
DE69535375T2 (de) 2007-11-08
AU708825B2 (en) 1999-08-12
CN1155904A (zh) 1997-07-30
ES2281899T3 (es) 2007-10-01
NO325828B1 (no) 2008-07-28

Similar Documents

Publication Publication Date Title
DK0758383T3 (da) Oplöselige polypeptidfraktioner af LAG-3-proteinet; fremgangsmåde til fremstilling; terapeutisk sammensætning; antiidiotypisk antistof
ATE430801T1 (de) Von wd-40 abstammende peptide und ihre verwendung
ATE404583T1 (de) Funktionelle antagonisten von hedgehog-aktivität
YU79491A (sh) Varijantni cd44-površinski proteini, dna-sekvence koje ih kodiraju i antitela protiv ovih proteina
DK1129186T3 (da) Et faktor VIII-polypeptid med faktor VIII:C-aktivitet
DE69926627D1 (de) Insulinartigen wachstumsfaktor bindendes protein -3 variante
DE69715181D1 (de) Peptid der löslichen form von acetylcholinesterase mit aktivität als calciumkanalmodulator
DE69426076T2 (de) Gereinigte flt3 liganden von saeugentieren, agonisten und antagonisten davon
DE69333952D1 (de) Klonering von dem gen für das t gondii protein gp 28.5 peptidfragmente aus diesem protein und ihre verwendungen.
DE69607034T2 (de) Pcna bindende substanz
ATE356831T1 (de) Neuer galaninrezeptor
PT773999E (pt) Receptor orfao or-1 pertencente a familia de receptores nucleares
DE59813388D1 (de) Polypeptide mit Aminosäuresequenzen aus dem N-terminalen Bereich von gp116 von Cytomegalovirus und deren Verwendung bei der Diagnostik, Prophylaxe und Therapie
SE9604439D0 (sv) New receptor